Polskie Archiwum Medycyny Wewnętrznej
-
Pol. Arch. Med. Wewn. · Mar 2021
Epicardial, pericardial fat and glucagon-like peptide-1 and 2 receptors expression in stable patients with multivessel coronary artery disease: an association with renin-angiotensin-aldosterone.
The expression of glucagon‑like peptide receptors (GLP‑Rs) in epicardial fat (EF) and pericardial fat (PF) depots might be involved in the pathogenesis of cardiovascular diseases. ⋯ In stable patients with MVD, the relative mRNA expression for both GLP receptors revealed significant associations with majority of analysed RAAS components.
-
Pol. Arch. Med. Wewn. · Mar 2021
Endoscopic treatment of rectal neuroendocrine tumors in a 13-year retrospective single-center study. Are we following the guidelines?
Rectal neuroendocrine neoplasms (rNENs) are potentially metastatic lesions. False endoscopic diagnosis and subsequent treatment may lead to nonradical resection and metastases. ⋯ In most cases, the origin of the lesion was not suspected on colonoscopy and subsequently the tumor was removed using an inappropriate method. Endoscopists do not follow the guidelines when dealing with patients with rNENs and more emphasis should be placed on education on the management of rNENs.
-
Pol. Arch. Med. Wewn. · Mar 2021
Determination of the optimal on-treatment diastolic blood pressure range using automated office measurements in patients without cardiovascular disease.
Optimal diastolic blood pressure (DBP) during antihypertensive treatment in patients without a history of cardiovascular disease (CVD) remains unknown. ⋯ Due to the fact that the range determined by the second method was wide and substantially different from the one recommended by the European Society of Cardiology (70-79 mm Hg), we have concluded that a DBP range of 73.7 to 83.7 mm Hg, measured using AOBPM, should be considered optimal in patients without CVD.
-
Pol. Arch. Med. Wewn. · Mar 2021
Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
According to the current data, there has been no increase in the incidence of COVID‑19 in patients with inflammatory bowel disease (IBD). ⋯ Patients with IBD may be at higher risk of developing SARS‑CoV‑2 infection, defined as the presence of elevated levels of anti-SARS‑CoV‑2 IgG antibodies, but not of having a symptomatic and / or severe course of COVID‑19 compared with healthcare professionals without IBD.